Abbott Laboratories Corporation

Abbvie Inc.

Curt S Cooper

David D Anderson

Rolf Wagner

Daniel T Chu

Christopher E Motter

Zhenkun Ma

Todd Warren Rockway

Michael D Tufano

David A Betebenner

Allan C Krueger

Anthony K Fung

Tami J Pilot-Matias

Rong Zhang

Jason P Shanley

Liangjun Lu

Robert J Carrick

Wenping He

Hongmei Mo

Dale J Kempf

Douglas M Kalvin

Darold L Madigan

Mira Hinman

Bruce A Beutel

Yu-Gui Gu

Nobuhiko Iwasaki

Sherie V L Masse

Akhteruzzaman Molla

Jacob J Plattner

John K Pratt

Dachun Liu

Clarence J Maring

Keith F McDaniel

Qun Li

Cheuk M Lee

Brian E Green

Teresa A Rosenberg

David A DeGoey

Pamela L Donner

Hong Yong

Xenia Beebe Searle

David J Grampovnik

Moshe Weitzberg

Robert F Keyes

William Sanders

Wei-Bo Wang

Daniel P Larson

Linda M Lynch

Todd D Bosse

Caroline David

Peter Dandliker

Larry L Klein

Richard F Clark

Todd M Hansen

Terry J Rosen

Ming Clinton Yeung

Hui-Ju J Chen

Andre G Pernet

Tianyuan Zhang

Fabio Palazzo

Sherie Vl Masse

Tamara Rehm

Akteruzzaman Molla

Weping He

This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.

HCV protease inhibitors and uses thereof

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Antibacterials having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

Antibacterial compounds

Bacterial protein synthesis-inhibiting compounds having formula (I)  and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.

Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.

Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds wherein

Quinolizinone type compounds

Process for preparation of chiral cis-3,4-substituted pyrrolidine compounds having the formulas: ##STR1## and chiral 3,4-trans-substituted pyrrolidine compounds having the formulas: ##STR2## with the assistance of a streochemically directing chiral oxazolidinone moiety having the formula: ##STR3## wherein P, R and R.sup.1 are specifically defined, by sequential reaction of the compound or subsequent intermediates with an a,b-unsaturated add chloride, reaction with N-benzyl-N-(methoxymethyl)trimethyl-silylmethylamine and separating isomers by chromatography, hydrolytic removal of the oxazolidinone moiety, reaction with diphenylphosphoryl azide and triethylamine, and debenzylating; and novel intermediates of the process.

Process for synthesis of chiral cis-and trans-3-amino-4 substituted

Process for preparation of chiral cis-3,4-substituted pyrrolidine compounds having the formulas ##STR1## and chiral 3,4-trans-substituted pyrrolidine compounds having the formulas ##STR2## with the assistance of a stereochemically directing chiral oxazolidinone moiety having the formula ##STR3## wherein P, R and R.sup.1 are specifically defined, by sequential reaction of the compound or subsequent intermediates with an a,b-unsaturated acid chloride, reaction with N-benzyl-N-(methoxymethyl)trimethylsilylmethylamine and separating isomers by chromatography, hydrolytic removal of the oxazolidinone moiety, reaction with diphenylphosphoryl azide and triethylamine, and debenzylating; and novel intermediates of the process.

Process for synthesis of chiral cis- and trans-3-amino-4-substituted

Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is .dbd.CR.sup.6 --; R.sup.1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R.sup.2 is selected from the group consisting of ##STR2## R.sup.3 is halogen; R.sup.4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R.sup.5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR.sup.13 R.sup.14 ; and R.sup.6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

Growing community of inventors

Vernon Hills, IL, United States of America

Curt S Cooper